BioSphere Medical


received Food and Drug Administration approval for its Embocath Hydrophilic Infusion Catheter.

The catheter is for use in a procedure in which tumors and vascular malformations are treated by blocking their blood supply. The company plans to distribute the product through its U.S. direct field sales organization, and, pending CE mark approval, which is required for marketing within Europe, through its European direct sales force as well.

Shares of BioSphere closed at $10.61 Monday on the